首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL IN THE NEOADJUVANT TREATMENT OF WOMEN WITH HER2-POSITIVE, LOCALLY ADVANCED, INFLAMMATORY OR EARLY BREAST CANCER IN PORTUGAL

【24h】

ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL IN THE NEOADJUVANT TREATMENT OF WOMEN WITH HER2-POSITIVE, LOCALLY ADVANCED, INFLAMMATORY OR EARLY BREAST CANCER IN PORTUGAL

机译：葡萄牙妥妥珠单抗联合曲妥珠单抗和多西他赛对葡萄牙HER2阳性，局部晚期，炎症或早期乳腺癌的新辅助治疗妇女的经济评价

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2016年第7期|共2页
作者
Ribeiro I; Lourenco O.; Alves C.; Thuresson P.; Monteiroa I; Batel-Marques F.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词
入库时间 2022-08-18 19:56:02

相似文献

外文文献
中文文献
专利

1. ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL IN THE NEOADJUVANT TREATMENT OF WOMEN WITH HER2-POSITIVE, LOCALLY ADVANCED, INFLAMMATORY OR EARLY BREAST CANCER IN PORTUGAL [J] . Ribeiro I, Lourenco O., Alves C., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：葡萄牙妥妥珠单抗联合曲妥珠单抗和多西他赛对葡萄牙HER2阳性，局部晚期，炎症或早期乳腺癌的新辅助治疗妇女的经济评价
2. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial: Commentary [J] . ThillM. Breast care . 2012,第2期

机译：新辅助性帕妥珠单抗和曲妥珠单抗在患有局部晚期，炎症或早期HER2阳性乳腺癌（NeoSphere）的女性中的疗效和安全性：一项随机，多中心，开放标签的2期试验：评论
3. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. [J] . Gianni L, Pienkowski T, Im YH, The lancet oncology . 2012,第1期

机译：新辅助性帕妥珠单抗和曲妥珠单抗在患有局部晚期，炎症性或早期HER2阳性乳腺癌（NeoSphere）的女性中的疗效和安全性：一项随机，多中心，开放标签的2期临床试验。
4. Functional Imaging of Neoadjuvant Chemotherapy Response in Women with Locally Advanced Breast Cancer using Diffuse Optical Spectroscopy [C] . Hany Soliman, Martin J. Yaffe, Gregory J. Czarnota Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2009

机译：弥漫光学光谱学局部晚期乳腺癌女性新辅助化疗反应的功能成像
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Biomarker analysis of the NeoSphere study: pertuzumab trastuzumab and docetaxel versus trastuzumab plus docetaxel pertuzumab plus trastuzumab or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer [O] . Giampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, 2017

机译：NeoSphere研究的生物标志物分析：帕妥珠单抗曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛用于HER2阳性乳腺癌的新辅助治疗
7. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer [O] . 2017

机译：NeoSphere研究的生物标志物分析：帕妥珠单抗，曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛，帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛对HER2阳性乳腺癌的新辅助治疗

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号